- -- 12 November 2012
- immatics appoints Peter Chambré as Chairman
- -- 08 November 2012
- immatics’ renal cancer vaccine IMA901 completes phase 3 patient recruitment and is granted US orphan drug designation by the FDA
- -- 27 September 2012
- IMA950 Phase I results presented by Allan James at ESMO 2012 (Sept. 30) in Vienna
- -- 28 August 2012
- IMA950 data presented by Roy Rampling at EANO 2012 (Sept. 7) in Marseille
- -- 29 July 2012
- immatics announces publication of IMA901 cancer vaccine data in Nature Medicine: immune response associates with longer survival
- -- 01 June 2012
- immatics presents encouraging overall survival data from a phase 2 study in Advanced Colorectal Cancer at the ASCO Annual Meeting
- -- 25 May 2012
- immatics presenting at ASCO Annual Meeting 2012 (June 1-5) in Chicago
- -- 25 May 2012
- immatics wins 2012 TiE50 Award
- -- 22 May 2012
- immatics at CIMT Annual Meeting 2012 starting tomorrow in Mainz, Germany
- -- 03 May 2012
- Harpreet Singh, CSO at immatics, will present at Immunotherapy Leaders’ Forum 2012 (May 9-11) in Barcelona, Spain
- -- 19 April 2012
- Paul Higham, CEO at immatics, will present at BioTrinity 2012 (April 24-26) in Newbury, Berkshire, UK
- -- 12 April 2012
- immatics appoints Dr Rainer Kramer as Chief Business Officer
- -- 01 April 2012
- immatics and collaborators publish preclinical results for Glioma Vaccine IMA950 in "Brain"
- -- 24 January 2012
- immatics presents positive Phase II results with its therapeutic cancer vaccine IMA910 in patients with advanced colorectal cancer at the ASCO Gastrointestinal Cancers Symposium
immatics appoints Dr Rainer Kramer as Chief Business Officer
immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing therapeutic vaccines that are active against cancer, today announced the appointment of Dr. Rainer Kramer as Chief Business Officer (CBO) with immediate effect.
In this newly created role, Dr. Kramer will lead immatics’ Business Development Unit in order to create optimal value from the Company’s pipeline of therapeutic cancer vaccines.
Dr. Kramer has many years of business development experience within the pharmaceutical industry. He joins from Signature Diagnostics, an oncology diagnostics company where he was CBO. Before that, he was Vice President Business Development at Jerini AG, where he was responsible for all licensing, partnering, and alliance management activities, and played a key role in the sale of the Company to Shire in 2008. Before joining Jerini, he held various business development and research positions at MorphoSys AG, Martinsried, and Amgen Inc. Dr. Kramer holds a Diploma in Molecular Biology from the University of Regensburg and a PhD from the Max-Planck-Institute for Neurobiology.
“Rainer’s appointment is a further important step in advancing our business strategy aimed at maximizing the potential of our TUMAP-based therapeutic cancer vaccine pipeline”, said Paul Higham, CEO of immatics. “The positive clinical results that we have already generated with our lead products IMA901, for advanced renal cancer, and IMA910, for advanced colorectal cancer, highlight our potential to make a real difference to the management of these difficult to treat cancers. Rainer’s strong business and deal-making experience will be a great asset as we seek partners where appropriate to help us to progress our vaccine candidates to market.”
Rainer Kramer said: “The impressive data with IMA901 and IMA910 confirm the tremendous potential of this novel class of therapeutic vaccines. I am delighted to be joining immatics at such an exciting time and look forward to making a significant contribution to the successful implementation of the Company’s corporate strategy, which is expected to deliver significant shareholder value and much improved treatment options for cancer patients.”